Neumora FY2025 net loss $236.9M; NMRA-511 positive data; NMRA-215 delayed to Q1 2027; cash to Q3 2027

Neumora Therapeutics, Inc.

Cash $182.5M; FY net loss $236.9M; R&D $176.1M, G&A $60.1M; cash runway into Q3 2027.
NMRA-511: pre-specified analysis (NPI-AA≥4) shows Cohen's d 0.34 on CMAI total, 0.51 on CMAI aggression.
Navacaprant: KOASTAL-2 and -3 fully enrolled (>400 each); topline readout expected Q2 2026.
M4 franchise: NMRA-898 lead; Phase 1 shows ~80-100h half-life, target engagement; MAD study data H2 2026.
NMRA-215: 12-week DIO data supports switch/maintenance; tox finding in 5/142 rats; clinical now Q1 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Neumora Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 30, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-130372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.